This is an international, multicenter, parallel-group, randomized, double-blind,
placebo-controlled trial in patients who have been stabilized during hospitalization
for acute heart failure, evaluating the effect of in-hospital initiation
of dapagliflozin versus placebo on the clinical outcome of cardiovascular
death or worsening heart failure.
A Randomized, Double-blind, Placebo-controlled Trial Assessing the Impact
of Inclisiran on Major Adverse Cardiovascular Events in Participants With
Established Cardiovascular Disease (VICTORION-2 PREVENT)
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate
the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events
in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
A Post-authorization Safety Study to Evaluate the Incidence of and Risk
Factors for Severe and Fatal Infusion-related Reactions in Participants
Treated with Daratumumab (Intravenous or Subcutaneous)
STUDY ID: HALO
Principal Investigator: Karine Darbinyan, MD
Breast
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk
Node Positive and T3N0 Breast Cancer.
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer
Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase
III Clinical Trial
Evaluation of Lasofoxifene Combine with Abemaciclib Compared with Fulvestrant
Combined with Abemaciclib in Locally Advanced or Metatstatic ER+/HR2-
Breast Cancer with an ESR1 Mutation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab
With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study.
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center
study assessing the efficacy and safety of durvalumab with SoC SBRT versus
placebo with SoC SBRT in patients with unresected clinical Stage I/II
lymph node-negative (T1 to T3N0M0) NSCLC.
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial
Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
(MAVERICK).
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic
Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation
for Locally Advanced Non-Small Cell Lung Cancer
This phase II trial compares the effect of oxybutynin versus placebo for
reducing hot flashes in men receiving androgen deprivation (hormone) therapy
for the treatment of prostate cancer. Androgen deprivation therapy decreases
testosterone and other androgens through medications or surgical removal
of the testicles. Relative to placebo, low- or high-dose oxybutynin may
reduce hot flashes in men receiving androgen deprivation therapy.
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating
De-Intensification for Lower Genomic Risk and Intensification of Concurrent
Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized,
Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
The Biorepository for Caris Life Sciences is designed for the purpose of
making quality biospecimens and associated clinical data available for
research studies related to advancing precision medicine and improving
care for patients.
.jpg)
.png)
